We investigated the clinical effects of bead size in irinotecan-loaded beads chemoembolization (DEBIRI) used for treating liver-dominant colorectal cancer. Between March 2009 and January 2018, all consecutive patients with colorectal cancer liver metastases referred for DEBIRI at our tertiary center were included in an observational study. Patients were treated exclusively with either 100-mg irinotecan-loaded DC beads of 70-150μm (small bead group or SB) or 100-300μm (large bead group or LB) in diameter, in addition to systemic therapy. Liver tumor response rate at 3months, liver and overall progression-free survival (PFS) and overall survival were estimated. In total, 84 patients with liver-dominant progressive disease underwent 232 DEBIRI sessions. Fifty-four patients were treated in the SB group and 30 patients in the LB group. Liver progression-free rates at 3months were 86.7% for the LB group and 79.6% for the SB group (NS). Median liver-PFS and overall PFS were, respectively, 7.15months and 7.15months for the LB group and 7.65 and 7.55months for the SB group (NS). Median overall survival was 13.04months for the LB group and 15.59months for the SB group (p = 0.04). Specific treatment grade 3 + 4 toxicity occurrence was 5 (17%) in the LB group and 20 (37%) in the SB group. No significant difference in patient outcome was observed between DEBIRI bead sizes of 70-150μm and 100-300μm. A trend toward higher treatment-specific toxicity was observed with the smaller beads.
Read full abstract